X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
MT-1303 (amiselimod HCl) is a sphingosine-1-phosphate receptor functional antagonist, which is being evaluated in Phase II clinical trial studies with patients for the treatment of ulcerative colitis.
Lead Product(s): Amiselimod HCl
Therapeutic Area: Gastroenterology Product Name: MT-1303
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Arestin® (minocycline hydrochloride) is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis, in adults with periodontitis.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Arestin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dental and Oral Health Product Name: Arestin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ORAPHARMA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.
Lead Product(s): Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments.
Lead Product(s): Chlordiazepoxide,Amitriptyline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Limbitrol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MedQuímica Indústria Farmacêutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 28, 2022
Details:
RELISTOR (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Salix Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Lead Product(s): Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology Product Name: Ryaltris
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2022
Details:
XIFAXAN (rifaximin) 200 mg tablets are indicated for travelers diarrhea. XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Alvogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
